We assessed whether EPO, previously described to alleviate renal fibrosis in CKD (Geng, Hu, & Lian, 2015), and FG‐4592, could impact markers associated with renal fibrosis, including type I (Col1a1) and type III collagen (Col3a1). Here, EPO is linked to chronic kidney disease.